For the small molecule EGFR inhibitor (EGFRi) erlotinib in NSCLC, skin rash and serum proteomic assays were initially identified as candidate predictive biomarkers [8]–[10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.